Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.66 | N/A | -13.40% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.66 | N/A | -13.40% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their pipeline and future projects. They emphasized their commitment to innovation despite current setbacks.
Management highlighted ongoing development efforts and future potential.
They acknowledged the challenges faced but remain focused on long-term goals.
Crinetics Pharmaceuticals reported a loss that was slightly worse than expected, which typically raises concerns among investors. However, the stock saw a modest increase of 0.32%, indicating that investors may be looking past the EPS miss to focus on the company's long-term potential. Management's optimistic tone about ongoing projects may have contributed to the positive stock reaction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MCCORMICK & CO INC Class N
Mar 30, 2021